AAAAAA
Results:
1-24
|
Results: 24
Authors:
Munekata, M
Kamata, O
Shirasaka, T
Higuchi, T
Citation: M. Munekata et al., Degree of crystallization and contamination effect on ferroelectric ceramic powder produced by fine grinding, JPN J A P 1, 40(9B), 2001, pp. 5638-5641
Authors:
Shirasaka, T
Miyahara, S
Kunitake, T
Jin, QH
Kato, K
Takasaki, M
Kannan, H
Citation: T. Shirasaka et al., Orexin depolarizes rat hypothalamic paraventricular nucleus neurons, AM J P-REG, 281(4), 2001, pp. R1114-R1118
Authors:
Kato, T
Shimamoto, Y
Uchida, J
Ohshimo, H
Abe, M
Shirasaka, T
Fukushima, M
Citation: T. Kato et al., Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil, ANTICANC R, 21(3B), 2001, pp. 1705-1712
Authors:
Iizuka, M
Saito, H
Yukawa, M
Itou, H
Shirasaka, T
Chiba, M
Fukushima, T
Watanabe, S
Citation: M. Iizuka et al., No evidence of persistent mumps virus infection in inflammatory bowel disease, GUT, 48(5), 2001, pp. 637-641
Authors:
Shirasaka, T
Miyahara, S
Takasaki, M
Kannan, H
Citation: T. Shirasaka et al., Nociceptin/orphanin FQ and [Phe(1)psi(CH2-NH)Gly(2)]nociceptin(1-13)NH2 modulates the activity of hypothalamic paraventricular nucleus neurons in vitro, BRAIN RES, 890(1), 2001, pp. 147-153
Authors:
Kannan, H
Kunitake, T
Kato, K
Saita, M
Shirasaka, T
Nose, K
Jin, QH
Ishizuka, Y
Citation: H. Kannan et al., Adaptive changes in the sympathetic nervous and endocrine systems during fever induced by interleukin-1 beta in conscious rats: Potential neural mechanism, THERMOTHERAPY FOR NEOPLASIA INFLAMMATION, AND PAIN, 2001, pp. 280-289
Authors:
Yamaguchi, S
Shirasaka, T
Tamao, K
Citation: S. Yamaguchi et al., Tridurylboranes extended by three arylethynyl groups as a new family of boron-based pi-electron systems, ORG LETT, 2(26), 2000, pp. 4129-4132
Authors:
Kobayashi, K
Shirasaka, T
Yamaguchi, K
Sakamoto, S
Horn, E
Furukawa, N
Citation: K. Kobayashi et al., Molecular capsule constructed by multiple hydrogen bonds: self-assembly ofcavitand tetracarboxylic acid with 2-aminopyrimidine, CHEM COMMUN, (1), 2000, pp. 41-42
Authors:
Saga, Y
Suzuki, M
Sato, I
Shirasaka, T
Citation: Y. Saga et al., An in vitro examination of a 5-fluorouracil regimen involving 'intermittent' continuous venous infusion using cultured cell lines derived from ovarian cancers, ONCOL REP, 7(3), 2000, pp. 625-628
Authors:
Araki, H
Fukushima, M
Kamiyama, Y
Shirasaka, T
Citation: H. Araki et al., Effect of consecutive lower-dose cisplatin in enhancement of 5-fluorouracil cytotoxicity in experimental tumor cells in vivo, CANCER LETT, 160(2), 2000, pp. 185-191
Authors:
Shirasaka, T
Yamamitsu, S
Tsuji, A
Taguchi, T
Citation: T. Shirasaka et al., Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FPtherapy in Japan, INV NEW DR, 18(4), 2000, pp. 315-329
Authors:
Iizuka, M
Itou, H
Chiba, M
Shirasaka, T
Watanabe, S
Citation: M. Iizuka et al., The MMR question, LANCET, 356(9224), 2000, pp. 160-160
Authors:
Kobayashi, K
Shirasaka, T
Horn, E
Furukawa, N
Citation: K. Kobayashi et al., Two-dimensional hexagonal hydrogen-bonded network with triangle-like largecavities: hexakis(4-carboxyphenyl)benzene, TETRAHEDR L, 41(1), 2000, pp. 89-93
Authors:
Kobayashi, K
Shirasaka, T
Sato, A
Horn, E
Furukawa, N
Citation: K. Kobayashi et al., Self-assembly of a radially functionalized hexagonal molecule: Hexakis(4-hydroxyphenyl)benzene, ANGEW CHEM, 38(23), 1999, pp. 3483-3486
Authors:
Nishiyama, M
Yamamoto, W
Park, JS
Okamoto, R
Hanaoka, H
Takano, H
Saito, N
Matsukawa, M
Shirasaka, T
Kurihara, M
Citation: M. Nishiyama et al., Low-dose cisplatin and 5-fluorouracil in combination can repress increasedgene expression of cellular resistance determinants to themselves, CLIN CANC R, 5(9), 1999, pp. 2620-2628
Authors:
Hirata, K
Horikoshi, N
Aiba, K
Okazaki, M
Denno, R
Sasaki, K
Nakano, Y
Ishizuka, H
Yamada, Y
Uno, S
Taguchi, T
Shirasaka, T
Citation: K. Hirata et al., Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug, CLIN CANC R, 5(8), 1999, pp. 2000-2005
Authors:
Cao, SS
Lu, K
Toth, K
Slocum, HK
Shirasaka, T
Rustum, YM
Citation: Ss. Cao et al., Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model, CLIN CANC R, 5(2), 1999, pp. 267-274
Authors:
Mizutani, Y
Wu, XX
Yoshida, O
Shirasaka, T
Bonavida, B
Citation: Y. Mizutani et al., Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil, ONCOL REP, 6(5), 1999, pp. 979-982
Authors:
Sohma, H
Hashimoto, E
Shirasaka, T
Tsunematsu, R
Ozawa, H
Boissl, KW
Boning, J
Riederer, P
Saito, T
Citation: H. Sohma et al., Quantitative reduction of type I adenylyl cyclase in human alcoholics, BBA-MOL BAS, 1454(1), 1999, pp. 11-18
Authors:
Shirasaka, T
Nakazato, M
Matsukura, S
Takasaki, M
Kannan, H
Citation: T. Shirasaka et al., Sympathetic and cardiovascular actions of orexins in conscious rats, AM J P-REG, 277(6), 1999, pp. R1780-R1785
Authors:
Shirasaka, T
Kunitake, T
Kato, K
Takasaki, R
Kannan, H
Citation: T. Shirasaka et al., Nociceptin modulates renal sympathetic nerve activity through a central action in conscious rats, AM J P-REG, 277(4), 1999, pp. R1025-R1032
Authors:
Kato, K
Shirasaka, T
Kunitake, T
Hanamori, T
Kannan, H
Citation: K. Kato et al., Participation of arterial baroreceptors input and peripheral vasopressin in the suppression of renal sympathetic nerve activity induced by central salt loading in conscious rats, J AUTON NER, 76(2-3), 1999, pp. 83-92
Authors:
Kobayashi, K
Shirasaka, T
Horn, E
Furukawa, N
Citation: K. Kobayashi et al., Self-assembly of cavitand tetracarboxylic acid: highly porous packing structure of one-dimensional hydrogen-bonded network, TETRAHEDR L, 40(50), 1999, pp. 8883-8886
Authors:
Ohno, T
Yano, SG
Yamada, H
Shirasaka, T
Yamamoto, A
Kobayashi, K
Ogawa, K
Citation: T. Ohno et al., Synthesis of the optical isomers of 4-[1-(4-tert-butylphenyl)-2-oxo-pyrrolidine-4-yl]methyloxybenzoic acid (S-2) and their biological evaluation as antilipidemic agent, CHEM PHARM, 47(11), 1999, pp. 1549-1554
Risultati:
1-24
|